Actors Benedix Ramos (left) and Justin Basobas are among the regular characters in the six episode series, “All the Things I Leave You (Patawid).” The trailer has gone viral with more than 4 million ...

Advanced glycation end products (AGEs) are irreversible adducts formed when reducing sugars react nonenzymatically with the amino groups lysine and arginine on proteins. Schiff bases and Amadori ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus ...

Technological advancement has become a leading cause of economic growth and global influence. The innovation nations, research nations, and technologically advanced nations are setting the future ...

Palo Alto Networks recently incorporated AI-driven data security into its secure access service edge (SASE) platform that can now helps customers defend against sophisticated web threats within ...

Google is sharing more information on how Chrome operates when Android mobile users enable Advanced Protection, highlighting strong security improvements. The tech giant recently extended its Advanced ...

LONDON, ENGLAND - APRIL 28: Zero emission branding is displayed on a Kia all electric British Transport Police car is displayed during the Fully Charged Live UK at Farnborough International on April ...

Bitcoin could turn parabolic if prices move above $115,000 to liquidate more than $7 billion in short positions. Onchain indicators enter overheated territory, suggesting prolonged profit taking from ...

The FDA approval—adding to five previous approvals for CABOMETYX—is based on results from CABINET, a phase 3 pivotal trial evaluating CABOMETYX compared with placebo in two cohorts of patients with ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...